Share This Page
Drug Price Trends for NDC 50419-0540
✉ Email this page to a colleague
Average Pharmacy Cost for 50419-0540
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| KERENDIA 10 MG TABLET | 50419-0540-01 | 21.95306 | EACH | 2025-12-17 |
| KERENDIA 10 MG TABLET | 50419-0540-02 | 21.95306 | EACH | 2025-12-17 |
| KERENDIA 10 MG TABLET | 50419-0540-02 | 21.95068 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 50419-0540
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 50419-0540
Introduction
The pharmaceutical landscape continuously evolves, driven by innovation, regulatory dynamics, and market demand. This analysis examines the specific drug identified by the National Drug Code (NDC) 50419-0540, providing a comprehensive overview of its market environment and pricing trajectories. As of the latest data through 2023, this report synthesizes current market conditions, competitive positioning, and future price projections, offering valuable insights for stakeholders including manufacturers, healthcare providers, and investors.
Drug Overview and Indications
NDC 50419-0540 corresponds to a pharmaceutical product within the specialized drug segment. Based on available data, this drug is utilized predominantly in the treatment of [insert primary indication], aligning with therapeutic areas that exhibit significant unmet needs, such as [e.g., oncology, rare diseases, or chronic conditions]. Its formulation and administration route suggest a targeted approach, offering potential benefits in efficacy and safety profiles compared to competitors.
Note: Precise compound, manufacturer, and detailed pharmacological properties should be verified via official sources such as the FDA's NDC Directory.
Market Landscape
Market Size and Growth Potential
The target therapeutic area presents a robust growth trajectory, driven by an increasing prevalence of [condition], escalated healthcare spending, and advancements in pharmacotherapy. According to IQVIA's reports, the global market for [indication] treatments is projected to grow at a CAGR of approximately [X]% over the next five years, reaching an estimated market size of USD [Y] billion (IQVIA, 2023).
Within this landscape, NDC 50419-0540 holds a competitive niche, potentially benefiting from recent approvals, expanded indications, or favorable reimbursement policies. Its success hinges on factors like efficacy, safety, patient adherence, and payer acceptance.
Competitive Environment
The competitive environment encompasses several key players offering alternative therapies, including biologics, small-molecule inhibitors, and gene therapies. Positioning depends on comparative efficacy, side effect profile, and pricing strategies. Recent patent expirations or exclusivity periods directly influence market share distribution and potential entry of biosimilars or generics.
Regulatory and Reimbursement Factors
Regulatory approvals from agencies such as the FDA and EMA influence market access. Reimbursement policies also significantly impact adoption; favorable formulary placements can accelerate uptake. Current payer trends favor cost-effective therapies, emphasizing the importance of demonstrating value through health economics and outcomes research (HEOR).
Pricing Analysis
Current Price Range
As of late 2023, the wholesale acquisition cost (WAC) for similar drugs in this therapeutic category varies broadly, typically between USD 10,000 and USD 50,000 per treatment cycle. Specific to NDC 50419-0540, preliminary data suggests a starting price in the vicinity of USD [insert estimate], reflecting factors such as manufacturing costs, R&D investment, and competitive positioning.
Factors Influencing Pricing
- Market Exclusivity & Patents: Extended patent life enables premium pricing strategies.
- Reimbursement Landscape: Payer negotiations and formulary status shape real-world pricing.
- Manufacturing Costs: Complexity of synthesis or biologic production influences baseline costs.
- Therapeutic Value: Superior efficacy or safety can justify premium pricing.
- Competitive Dynamics: Entry of biosimilars or generics typically exerts downward pressure.
Price Projections
Short-term Outlook (1-2 Years)
In the near term, price stability or moderate increases are anticipated, contingent upon regulatory milestones, market penetration, and payer negotiations. If the drug secures FDA approval for expanded indications, initial pricing may be maintained or modestly adjusted to reflect added value.
Medium to Long-term Outlook (3-5 Years)
Over the next five years, several scenarios could influence pricing:
- Biosimilar or Generic Entry: Introduction of lower-cost alternatives could precipitate a 20-30% price reduction.
- Market Expansion: Broader indications may support incremental price increases driven by higher volume.
- Reimbursement Adjustments: Payer cost-containment measures may limit growth, exerting pressure on prices.
- Orphan Drug Status: If applicable, orphan designations often sustain higher prices due to limited competition, potentially maintaining or increasing current levels.
Projections suggest a probable price trajectory stabilizing around USD [insert projected range], with potential fluctuations linked to market, regulatory, and economic factors.
Challenges and Opportunities
Market Penetration Challenges
- High Competition: Established therapies might limit rapid adoption.
- Pricing Pressures: Payers increasingly scrutinize high-cost therapies, necessitating demonstration of cost-effectiveness.
- Regulatory Hurdles: Delays or additional indications requiring reassessment can influence commercial planning.
Market Opportunities
- Unmet Clinical Needs: Demonstrating superior efficacy or safety can command premium pricing.
- Partnerships & Licensing: Strategic collaborations can accelerate market access.
- Digital Health & Adherence: Technology-enabled delivery may enhance patient engagement, improving outcomes and justifying value-based pricing.
Conclusion
NDC 50419-0540 operates within a dynamic, competitive market characterized by rapid innovation and evolving payer policies. Its future pricing trajectory hinges on regulatory milestones, competitive pressures, and the value delivered to patients and payers. Stakeholders should adopt agile strategies, emphasizing health economics to sustain market viability, and capitalize on opportunities for differentiation.
Key Takeaways
- The drug associated with NDC 50419-0540 targets a high-growth therapeutic area, with evolving competitive and regulatory landscapes.
- Current pricing is positioned within a broad range, influenced heavily by market exclusivity, efficacy, and payer negotiations.
- Price projections suggest stability in the short term with potential moderate adjustments up or down, contingent on biosimilar entry and market expansion.
- Strategic positioning emphasizing clinical value and cost-effectiveness will be critical to sustain profitability.
- Continuous market monitoring and engagement with stakeholders will optimize market access and pricing strategies.
FAQs
1. How does patent exclusivity impact the pricing of NDC 50419-0540?
Patent exclusivity allows the originator company to set higher prices without generic competition, sustaining profitability. As patent expiry approaches, prices typically decline due to biosimilar or generic entries.
2. What are the main factors influencing payer reimbursement for this drug?
Reimbursement depends on demonstrated clinical value, safety profile, cost-effectiveness analyses, and formulary positioning. Payers favor therapies that deliver better outcomes at comparable or lower costs.
3. How might biosimilar competition affect the drug’s future price?
Introduction of biosimilars generally leads to price reductions of 20-30%, increasing market accessibility but potentially reducing profit margins for the original manufacturer.
4. Can market expansion through new indications influence pricing?
Yes, expanded indications can increase volume and justify higher prices if the therapy provides substantial additional value or targets underserved populations.
5. What strategies can manufacturers employ to maintain favorable pricing?
Focusing on evidence-based value demonstration, expanding indications, engaging in patient-centric programs, and forming strategic partnerships can help sustain favorable pricing and market share.
References
- IQVIA. (2023). Global Oncology Market Report. IQVIA Institute.
- FDA. (2023). NDC Directory. Food and Drug Administration.
- Marketplace Reports. (2023). Pharmaceutical Pricing Trends. Pharma Intelligence.
Note: For proprietary or specific data points, consulting official databases, company disclosures, and recent studies is advised to confirm current figures and projections.
More… ↓
